Compare CNXN & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXN | ARDX |
|---|---|---|
| Founded | 1982 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 1998 | 2014 |
| Metric | CNXN | ARDX |
|---|---|---|
| Price | $62.35 | $6.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $12.95 |
| AVG Volume (30 Days) | 98.7K | ★ 4.1M |
| Earning Date | 02-04-2026 | 02-19-2026 |
| Dividend Yield | ★ 1.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.27 | N/A |
| Revenue | ★ $2,872,746,000.00 | $398,234,000.00 |
| Revenue This Year | $7.84 | $22.44 |
| Revenue Next Year | $5.55 | $34.00 |
| P/E Ratio | $19.52 | ★ N/A |
| Revenue Growth | 2.52 | ★ 58.12 |
| 52 Week Low | $54.97 | $3.21 |
| 52 Week High | $71.17 | $8.40 |
| Indicator | CNXN | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 54.96 | 42.52 |
| Support Level | $63.35 | $6.92 |
| Resistance Level | $68.88 | $7.43 |
| Average True Range (ATR) | 2.39 | 0.32 |
| MACD | 0.25 | -0.15 |
| Stochastic Oscillator | 49.73 | 4.48 |
PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.